CasNo.501692-44-0,Odevixibat,1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl})carbamoylmethoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine(501692-44-0) Suppliers

0	Negotiable

Min.Order :0
Purity: 98%

Keywords

Butanoic acid, 2-[[(2R)-2-[[2-[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-, (2S)- (2S)-2-[[(2R)-2-[[2-[[3,3-Dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid

Quick Details

Appearance:White to off-white solid
Application:For research use only.
PackAge:
ProductionCapacity:
Storage:Store at -20 °C, stored under nitrogen
Transportation:

Superiority:

We provide customized and high-quality Odevixibat product for your project.

Details:

Odevixibat is an ileal sodium/bile acid cotransporter inhibitor for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) older than 3 months. Odevixibat alleviates cholestatic liver and bile duct damage in mouse